|  |
| --- |
| **AUDIT PREPARATION CHECKLIST** |

If notified of an FDA inspection, the investigational site should contact the staff members associated with the particular trial. If notified of an FDA inspection, please refer to *Attachment B- FDA Inspection Notification Form*. Once completed, the site should work to review all trial documents to prepare for the inspection.

**Administrative**:

*Reserve a room, desk, and phone for the inspector(s). Be sure that the room is away from clinical activity and in a private setting.*

Protocol Name:\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Audit Date(s):\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Building & Room Number: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Phone Number: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

|  |  |
| --- | --- |
| **Regulatory**  Locate, organize, and review for accuracy the following items:  *Some items may not be applicable to all studies* | **Comments** |
| □ Delegation of Authority Log |  |
| * All IRB approvals filed |  |
| * Annual Reports/Continuing Reviews |  |
| * Financial Disclosures |  |
| * Investigator Statements or 1572s |  |
| * All protocol versions filed |  |
| * All ICF versions filed |  |
| * Master subject log |  |
| * List of PI’s active protocols |  |
| * Screening & Enrollment logs |  |
| * IND Safety reports |  |
| * Correspondence (IRB, Sponsor, and Monitor, Study team) |  |
| * Training Documents   + CVs   + GCP/CITI   + Protocol   + Additional training/certifications |  |
| * AE Reporting as applicable |  |
| **Review of Subjects**  Locate, organize, and review for accuracy the following items:  *Some items may not be applicable to all studies* | **Comments** |
| * ICFs complete, along with ICF process documentation   + Correct version used   + Re-consents, if applicable   + Both subject and person obtaining consent signed correctly |  |
| * Thorough documentation of subject eligibility for trial, with sign-off by the investigator |  |
| * Data in subject binders match the data entered in EDC |  |
| * Consistency among subject shadow charts |  |
| * All information filed |  |
| * PI oversight, including sign-off on AEs, labs, etc., as appropriate |  |
| * AE/SAEs appropriately reported and documented |  |
| * Protocol deviations appropriately reported and documented |  |
| *If your inspector does not request EMR or EDC access, it may be necessary to file information in subject binders related, but not limited to:*   * *Missed visits or procedures* * *Protocol deviations* * *Visits out of window* * *Missed re-consents* | |
| **Drug/Device Accountability & Ancillary Departments**  Locate, organize, and review for accuracy the following items:  *Some items may not be applicable to all studies* | **Comments** |
| * Most recent version of Investigator Brochure (IB) or Instructions for Use (IFU) |  |
| * Trainings, as applicable, for Pharmacists/lab managers |  |
| * Temperature Logs |  |
| * Most recent Pharmacy or Device Manual |  |
| * Accountability logs |  |
| * Shipping/ordering records and receipts |  |
| * Dispense records for study product |  |
| * Lab certifications |  |
| * Lab normal ranges |  |
| * Specimen logs |  |
| * Calibration and maintenance records of equipment |  |